• Predictive autoantibody biomarker signatures can be developed to identify drug responders and non-responders, and biologically relevant sub-cohorts.
  • These insights enable intra-disease stratification, driving more efficient and economical study designs and clinical trial patient enrichment.

Accelerating discovery of autoantibody signatures.

Sengenics can help, with solutions to support discovery of biomarker signatures. Our high-density protein microarray assays enable highly specific and reproducible detection of disease-relevant autoantibodies directly from patient serum.